HUMA - Humacyte, Inc. Stock Price, Fair Value and News

$4.12-0.27 (-6.15%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

HUMA Price Action

Last 7 days

-13.1%

Last 30 days

0.5%

Last 90 days

-29.1%

Trailing 12 Months

55.5%

HUMA RSI Chart

HUMA Valuation

Market Cap

518.5M

Price/Earnings (Trailing)

-3.39

Price/Sales (Trailing)

506.38

Price/Free Cashflow

-5.63

HUMA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

HUMA Fundamentals

HUMA Revenue

HUMA Earnings

Earnings (TTM)

-152.9M

Earnings Growth (Yr)

-50.81%

Earnings Growth (Qtr)

30.82%

HUMA Profitability

Return on Equity

239.9%

Return on Assets

-133.2%

Free Cashflow Yield

-17.77%

HUMA Investor Care

Shares Dilution (1Y)

21.52%

Diluted EPS (TTM)

-1.34

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	1.3M	2.0M	1.7M	1.6M
2021	3.7M	2.9M	2.1M	1.3M
2020	0	0	5.4M	4.5M
2019	0	0	0	6.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Humacyte, Inc.

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

CEO	Dr. Laura E. Niklason M.D., Ph.D.
WEBSITE	humacyte.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	164

Humacyte, Inc. Frequently Asked Questions

What is the ticker symbol for Humacyte, Inc.? What does HUMA stand for in stocks?

HUMA is the stock ticker symbol of Humacyte, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Humacyte, Inc. (HUMA)?

As of Tue Jan 14 2025, market cap of Humacyte, Inc. is 518.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HUMA stock?

You can check HUMA's fair value in chart for subscribers.

Is Humacyte, Inc. a good stock to buy?

The fair value guage provides a quick view whether HUMA is over valued or under valued. Whether Humacyte, Inc. is cheap or expensive depends on the assumptions which impact Humacyte, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HUMA.

What is Humacyte, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jan 14 2025, HUMA's PE ratio (Price to Earnings) is -3.39 and Price to Sales (PS) ratio is 506.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HUMA PE ratio will change depending on the future growth rate expectations of investors.